Puma
Biotechnology
26
0
25
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Melda Saglam, PhD
Hacettepe University
Shared therapeutic areas:
Daniel i Sessler, MD
The Cleveland Clinic
Shared therapeutic areas:
Britt Burton-Freeman, ph.D
Illinois Institute of Technology
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
min yan
Henan Cancer Hospital
Shared therapeutic areas:
Shirley Wang, PhD, ScM
Brigham and Women's Hospital
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (26)
Showing 20 of 26 trials
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
Study Evaluating Safety And Tolerability, Solid Tumor
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects
Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
Study Evaluating The Tolerability Of Multiple Doses Of HKI-272